High Market Potential
Bexion is currently pursuing cancer treatments where there is a significant unmet need and high market potential*.
|Bexion Area of Focus||Unmet Need||Annual Global Market Potential|
|DIPG – Diffuse Intrinsic Pontine Glioma||Currently, there are no approved drugs for DIPG
DIPG carries a dismal prognosis, with a 2-year survival rate of <10%, making DIPG one of the most fatal pediatric malignancies.
|$15 Million-Qualify for a Rare Pediatric Voucher|
|Glioblastoma Multiforme (GBM)||GBM average survival is 16-20 months, with only 25% of glioblastoma patients surviving 2 years.||$1 Billion|
|Colorectal||Stage 4 colorectal cancer 5-year survival rate is between 11 and 14%.||$10 Billion|
*BXQ-350 appears to be “tumor-agnostic” suggesting treatments for other types of cancer.